KYMR Q2 2023 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+43.4% YoY

Gross Profit

$17M100.0% margin

Operating Income

-$43M-262.7% margin

Net Income

-$39M-235.0% margin

EPS (Diluted)

$-0.67

QoQ Revenue Growth

+74.4%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$46M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$582M

Total Liabilities

$147M

Stockholders' Equity

$435M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$12M	+43.4%
Gross Profit	$17M	$12M	+43.4%
Operating Income	-$43M	-$41M	-6.3%
Net Income	-$39M	-$40M	+3.6%